Provention Bio Stock Forecast, Price & News

-0.10 (-1.18 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.21 million shs
Average Volume1.98 million shs
Market Capitalization$530.45 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PRVB News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

Provention Bio logo

About Provention Bio

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. The company was incorporated in 2016 and is headquartered in Red Bank, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.72 out of 5 stars

Medical Sector

273rd out of 2,100 stocks

Pharmaceutical Preparations Industry

131st out of 831 stocks

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Provention Bio (NASDAQ:PRVB) Frequently Asked Questions

Is Provention Bio a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Provention Bio stock.
View analyst ratings for Provention Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Provention Bio?

Wall Street analysts have given Provention Bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Provention Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Provention Bio?

Provention Bio saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 5,940,000 shares, an increase of 37.5% from the May 13th total of 4,320,000 shares. Based on an average trading volume of 2,570,000 shares, the short-interest ratio is currently 2.3 days. Currently, 11.6% of the shares of the stock are short sold.
View Provention Bio's Short Interest

When is Provention Bio's next earnings date?

Provention Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Provention Bio

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) issued its earnings results on Thursday, May, 6th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.04.
View Provention Bio's earnings history

How has Provention Bio's stock been impacted by COVID-19 (Coronavirus)?

Provention Bio's stock was trading at $9.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PRVB stock has decreased by 7.1% and is now trading at $8.37.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PRVB?

6 equities research analysts have issued 12 month price objectives for Provention Bio's shares. Their forecasts range from $10.00 to $27.00. On average, they anticipate Provention Bio's share price to reach $18.75 in the next year. This suggests a possible upside of 124.0% from the stock's current price.
View analysts' price targets for Provention Bio
or view top-rated stocks among Wall Street analysts.

Who are Provention Bio's key executives?

Provention Bio's management team includes the following people:
  • Mr. Ashleigh W. Palmer B.Sc., M.B.A., Co-Founder, Pres, CEO & Director (Age 58, Pay $874.15k)
  • Dr. Francisco Leon M.D., Ph.D., Co-Founder & Chief Scientific Officer (Age 49, Pay $603k)
  • Mr. Andrew T. Drechsler, Chief Financial Officer (Age 49, Pay $589.4k)
  • Dr. Eleanor L. Ramos, Chief Medical Officer (Age 65, Pay $635.6k)
  • Mr. Jason Hoitt, Chief Commercial Officer (Age 43, Pay $591.33k)
  • Mr. Robert A. Doody Jr., VP of Investor Relation
  • Ms. Heidy Abreu King-Jones J.D., L.L.M., Chief Legal Officer (Age 38)
  • Dr. Sherron Kell, Sr. VP of Clinical Devel.

Who are some of Provention Bio's key competitors?

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.04%), Gilder Gagnon Howe & Co. LLC (4.91%), Perceptive Advisors LLC (4.50%), Geode Capital Management LLC (1.37%), 683 Capital Management LLC (0.99%) and Northern Trust Corp (0.94%). Company insiders that own Provention Bio stock include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Eleanor Ramos, Francisco Leon and Jason Hoitt.
View institutional ownership trends for Provention Bio

Which institutional investors are selling Provention Bio stock?

PRVB stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, 683 Capital Management LLC, Morgan Stanley, Credit Suisse AG, Alliancebernstein L.P., Baker Avenue Asset Management LP, Citigroup Inc., and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Provention Bio
or view top insider-selling stocks.

Which institutional investors are buying Provention Bio stock?

PRVB stock was acquired by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, BlackRock Inc., Goldman Sachs Group Inc., Advisory Research Inc., Renaissance Technologies LLC, Millennium Management LLC, Geode Capital Management LLC, and Schonfeld Strategic Advisors LLC. Company insiders that have bought Provention Bio stock in the last two years include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Eleanor Ramos, Francisco Leon, and Jason Hoitt.
View insider buying and selling activity for Provention Bio
or or view top insider-buying stocks.

How do I buy shares of Provention Bio?

Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $8.37.

How much money does Provention Bio make?

Provention Bio has a market capitalization of $530.45 million. The company earns $-98,580,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Provention Bio have?

Provention Bio employs 59 workers across the globe.

What is Provention Bio's official website?

The official website for Provention Bio is

Where are Provention Bio's headquarters?

Provention Bio is headquartered at P.O. BOX 666, OLDWICK NJ, 08858.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at 908-336-0360 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.